Insider Makes Significant Stock buy in Esperion Therapeutics (ESPR) Shares Breaks neutral Trend of Last 90 Days
10:20 PM EDT, 05/10/2021 (MT Newswires) -- Significant insider buying activity was revealed in Esperion Therapeutics shares in a form 4 document filed with the SEC today, showing -- Target Biotech Nv, 10% Owner -- purchased 230,000 shares in the company having a net market value of approximately $4,648,482. This is the first insider buy/sell trade in the past 90 days.
The level of buy-sell trades at Esperion Therapeutics is close to that of the 207 member peer company average. The Biotechnology & Medical Research peer group saw 270 buy/sell trades during this period for an average of 1.3 transactions per company. However, trading at Esperion Therapeutics represents a lower number of shares per transaction. Within the peer group there were 102,899,632 shares purchased and 23,863,270 shares sold with company insiders purchasing 479,008 shares on average over this time period.
Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in creating and writing this story.
This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.